US researchers have revealed(link is external) the identity of molecules on the surface of cancer cells which allow the body’s immune system to identify and destroy them.
The research could lead to a new generation of immunotherapies that are far more effective than those currently in use, that could target a range of cancers.
“This is a huge breakthrough,” said Cancer Research UK’s Dr Sergio Quezada, who works at UCL in London and was not involved in the research.
“The researchers were looking for ‘signatures’ on the surface of cancer cells associated with response to current immunotherapies, but their findings go further than that. They’ve actually discovered molecular motifs that will inform the development of the next generation of therapies,” he added.
The researchers, led by a team at the Memorial Sloan Kettering Cancer Centre in New York, analysed cancer DNA from 64 melanoma patients who had been treated with an immunotherapy drug called ipilimumab, half of whom had responded to the drug.
Ipilimumab works by switching on the body’s immune system to attack their cancer, but – for unknown reasons – it only works effectively in a minority of patients.
“We’ve been using a drug that empirically was found to be quite effective, and yet we didn’t have a detailed understanding of how it was working in people,” said Memorial Sloan Kettering’s Dr Jedd Wolchok.
Having analysed the patients’ cancer DNA, the researchers used sophisticated software to look for genetic mutations in the cancer cells that could predict whether patients had, or hadn’t, responded to the drug.
In doing so, they uncovered a series of genetic mutations in some of the patients that caused the cancer cells to produce short stretches of protein molecules, called peptide antigens, that make cancerous cells visible to immune response.
Tantalisingly, it appears that these mutations cause the antigens to mimic small parts of proteins produced by bacteria and viruses, explaining why they are so effective at triggering the immune response – although the researchers say more research will be needed to confirm this.
The discovery is “big, big news” for immunotherapy researchers says Cancer Research UK’s Dr Quezada. “This is the first time we’ve had an idea of what the immune system actually ‘sees’ on a tumour. Until now, it’s been hot topic of debate,” he said.
The Latest on: Immunotherapies
via Google News
The Latest on: Immunotherapies
- Dragonfly Therapeutics Announces Collaboration with AbbVie for Autoimmune Diseases and Oncologyon November 20, 2019 at 4:10 pm
AbbVie receives exclusive options to license a number of Dragonfly's natural killer (NK) cell engager immunotherapies. WALTHAM, Mass., Nov. 20, 2019 /PRNewswire/ -- Dragonfly Therapeutics ("Dragonfly" ...
- Cellectis Wins Patent Challenge in Europe for a Method Using CRISPR-Cas9 for Gene Editing in T-Cellson November 20, 2019 at 12:30 pm
Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today announced that European ...
- Patients treated outside NCI centers less likely to receive high-cost lung cancer drugson November 20, 2019 at 1:57 am
Genetically targeted drugs and immunotherapies are transforming the way we treat many forms of lung cancer. However, a University of Colorado Cancer Center study published in the Journal of the ...
- Immunotherapies targeting melanoma post encouraging results, new data showon November 11, 2019 at 4:12 am
Iovance Biotherapeutics (IOVA) and Nektar Therapeutics (NKTR) presented notable clinical updates on their respective melanoma programs at the Society for Immunotherapy of Cancer annual meeting, which ...
- Ervaxx launches to pioneer use of Dark Antigens to develop off-the-shelf cancer vaccines, T-cell receptor-based immunotherapieson November 7, 2019 at 12:28 am
Ervaxx, a biotechnology company pioneering the use of Dark Antigens to develop off-the-shelf cancer vaccines and T-cell receptor-based immunotherapies, formally announces its launch following two ...
- Gritstone Oncology to Webcast Investor Event Reviewing its Neoantigen-based Immunotherapies During SITC Conferenceon October 31, 2019 at 5:02 am
EMERYVILLE, Calif., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight ...
- Bristol-Myers' immunotherapies show promise in lung cancer trial; shares riseon October 22, 2019 at 6:16 am
(Reuters) - Bristol-Myers Squibb Co said on Tuesday an interim analysis of a late-stage trial testing a combination of its immuno-oncology drugs Opdivo and Yervoy met the main goal of extending life ...
- Creatine powers fight against cancer, improves efficacy of immunotherapieson October 21, 2019 at 7:08 pm
The researchers at the University of California – Los Angeles Health Services conducted the study on mice showing taking creating supplements can make current immunotherapies more effective. "Because ...
- Inactive receptor renders cancer immunotherapies ineffectiveon October 16, 2019 at 5:22 am
The aim of immunotherapies is to enable the immune system to fight cancer on its own. Drugs known as checkpoint inhibitors are already in clinical use for this purpose. However, they are only ...
- ElevateBio Launches HighPassBio to Advance Novel Targeted T Cell Immunotherapies with Technology from Fred Hutchinson Cancer Research Centeron October 1, 2019 at 4:25 am
--(BUSINESS WIRE)--ElevateBio, a Cambridge-based biotechnology holding company, today announced it has established and launched HighPassBio, a company dedicated to advancing novel targeted T cell ...
via Bing News